Life Sciences

  • March 23, 2026

    Novartis Faces Class Suit Over Patient Health Info Disclosure

    Drugmaker Novartis collected patients' personal and health information through pharmaceutical marketing websites and transmitted it to third parties including Google using "surreptitious online tracking tools" without patients' consent, a proposed class action in New Jersey federal court alleges.

  • March 23, 2026

    Agilent, Axion End Cell Analysis IP Suit After Jury Selection

    Laboratory equipment company Agilent Technologies and biotechnology business Axion BioSystems have agreed to end litigation accusing Axion of patent infringement, just before trial was to start Monday.

  • March 23, 2026

    Federal Prosecutors Fight Bail Bid For Convicted Biotech CEO

    Federal prosecutors are fighting former CytoDyn CEO Nader Pourhassan's bid to stay free on bail while he appeals his securities fraud and insider trading convictions, arguing in Maryland federal court that the executive's arguments on appeal are little more than recycled versions of the failed claims he made in seeking a new trial.

  • March 23, 2026

    Feds Approve Minnesota's Plan To Combat Medicaid Fraud

    Minnesota may soon receive the release of $243 million in deferred Medicaid funds after the Centers for Medicare & Medicaid Services approved the state's updated plan to combat Medicaid fraud, Minnesota state health officials told a federal court last week.

  • March 23, 2026

    AbbVie Escapes Ill. Genetic Privacy Lawsuit

    An Illinois federal judge on Friday granted AbbVie summary judgment in a lawsuit claiming it violated the state's genetic privacy law, saying there was "no genuine dispute" that AbbVie never conditioned the plaintiff's employment on whether he disclosed genetic information in the physical exam he was required to undergo before starting work.

  • March 23, 2026

    High Court Won't Hear Mich. Newborn Blood Testing Case

    The U.S. Supreme Court on Monday declined to hear a petition from parents seeking to revive claims that the way newborn blood samples are collected and stored in a Michigan health screening program violates their rights to make medical decisions for their children.

  • March 23, 2026

    Fecal Treatment Co. Files Ch. 11 To Escape Lease, Sell IP

    A company that develops treatments to improve the health of the body's microbiome sought Chapter 11 protection, saying it had never generated a positive cash flow and faces unresolved litigation and a burdensome lease.

  • March 23, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court's docket this past week featured high-stakes disputes involving major consumer brands, a reinstated video game executive, revived noncompete and compensation claims and fresh allegations of corporate misconduct in the healthcare sector.

  • March 23, 2026

    Justices Won't Review Lab Owner's Kickback Conviction

    The U.S. Supreme Court on Monday declined to review the conviction of a former California biotech president sentenced to eight years in prison for lying about the efficacy of his company's COVID-19 and allergy testing and conducting a $70 million Medicare fraud scheme. 

  • March 23, 2026

    Justices Pass On Challenge To Courts' Sanctions Authority

    The U.S. Supreme Court on Monday declined a dietary supplement company's request to review sanctions it was issued at trial in a false advertising dispute, in a case that could have led justices to clarify when courts may use their inherent authority to sanction parties for litigation conduct.

  • March 20, 2026

    Feds Rip Ex-NFL Player's New Trial Bid Over Medicare Scheme

    The federal government opposed a new trial bid by Keith Gray, a former NFL player and Texas laboratory owner convicted in a $328 million scheme involving billing for unnecessary cardiovascular genetic testing for Medicare beneficiaries, arguing Thursday he lacks any valid basis to "disturb the jury's sound verdict."

  • March 20, 2026

    Former Gilead Sciences GC To Earn Over $2.5M Severance

    Gilead Sciences Inc. is paying its former general counsel more than $2.5 million in severance after she left the company, according to a U.S. Securities and Exchange Commission filing released Friday.

  • March 20, 2026

    CytoDyn Settles Investor Suit With $500K, 49M Shares

    Biotechnology firm CytoDyn has agreed to dole out 49 million shares of common stock and pay $500,000 to end investors' proposed class action accusing the company of overstating the likelihood that the U.S. Food and Drug Administration would approve a drug it claimed could treat HIV and COVID-19.

  • March 20, 2026

    Feds To Cover Ayahuasca Church's Legal Fees, 9th Circ. Says

    The federal government is on the hook for more than $2 million in attorney fees following a settlement with a Phoenix-based church over its right to use the psychedelic beverage ayahuasca in religious ceremonies, a divided Ninth Circuit panel said in an unpublished opinion Friday.

  • March 20, 2026

    EPA's Ethylene Oxide Plan May Hinder Other Air Toxics Regs

    A new proposal from the U.S. Environmental Protection Agency to weaken emission standards for a medical sterilizer could have broader implications for the agency's power to tighten air pollution limits when new science becomes available.

  • March 20, 2026

    Eli Lilly Beats 9th Circ. Appeal Over Brain Bleed After Cialis

    A Ninth Circuit panel Friday upheld Eli Lilly and Co.'s win over a Washington man who claimed the company's erectile dysfunction drug Cialis caused bleeding in his brain, ruling David Dearinger failed to establish that doctors would have acted differently had they been warned of the medication's risks.

  • March 20, 2026

    IVF Patients Say Co. Misled Them On Genetic Test's Accuracy

    A genetic testing company misled consumers about the accuracy and efficacy of a test marketed to patients going through in-vitro fertilization, according to a proposed class action filed in New Jersey federal court.

  • March 20, 2026

    Fed. Circ. Backs Military In Veterinary Software Dispute

    The Federal Circuit on Friday ruled in favor of the government in a dispute with a subcontractor over rights to healthcare software for a U.S. Army veterinary records system, affirming a lower court finding that the contractor failed to present a valid contract claim and could not pursue a copyright infringement claim based on defective registrations.

  • March 20, 2026

    Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit

    Telehealth company Hims & Hers Health Inc. urged a California federal court to release it from a shareholder suit accusing it of exploiting its partnership with Novo Nordisk, the distributor of weight loss drug Wegovy, to sell "knockoff" drugs, saying the suit does not allege the company's executives knew the partnership would fall through.

  • March 20, 2026

    Beasley Allen Can't Halt DQ Ruling In J&J Talc Litigation

    A New Jersey state appeals court has refused to pause its decision disqualifying the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, according to a court order.

  • March 20, 2026

    Hong Kong Backer Accuses Med Co. Founders Of Self-Dealing

    A Hong Kong-based investor has filed a lawsuit in the Delaware Chancery Court accusing the founders of a medical device startup of running the company for their own benefit while ignoring basic corporate governance rules.

  • March 20, 2026

    Prestige Picks Up Breathe Right In $1.05B Deal

    Consumer healthcare company Prestige Consumer Healthcare Inc. revealed on Friday that it has agreed to acquire a portfolio of brands including Breathe Right nasal strips from Foundation Consumer Healthcare, advised by Skadden Arps Slate Meagher & Flom LLP, in a $1.05 billion deal.

  • March 19, 2026

    4th Circ. Leery Of W.Va. Opioid Towns' Abatement Arguments

    During a heated hourlong oral argument Thursday, two Fourth Circuit judges interrogated an attorney for West Virginia municipalities stricken by the opioid crisis about whether the public nuisance of overly available drugs had already been abated, leaving only redress of resulting harms.

  • March 19, 2026

    Chan Zuckerberg Initiative Hit With Gender Bias Action

    The Chan Zuckerberg Initiative LLC run by Meta Platforms Inc. CEO Mark Zuckerberg and his wife Priscilla Chan discriminated against women by routinely paying them less than men and promoting them with less frequency, according to a proposed class and collective action removed Wednesday to California federal court.

  • March 19, 2026

    Pharma Group Can't Halt Colo. Law Over Drug Discount Rules

    A Colorado federal judge denied a bid by the Pharmaceutical Research and Manufacturers of America seeking to halt enforcement of a state law guarding providers' ability to contract with pharmacies to distribute discounted drugs under the federal 340B program.

Expert Analysis

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

  • Courts Are Still Grappling With McDonnell, 9 Years Later

    Author Photo

    The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.

  • AI Will Transform Patent Examination For The Better

    Author Photo

    The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.

  • Hybrid Claims In Antitrust Disputes Spark Coverage Battles

    Author Photo

    Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.

  • Drug Ad Crackdown Demonstrates Admin's Aggressive Stance

    Author Photo

    Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.

  • Protecting Sensitive Court Filings After Recent Cyber Breach

    Author Photo

    In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.

  • Series

    Judging Figure Skating Makes Me A Better Lawyer

    Author Photo

    Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.

  • Trending At The PTAB: Petitioners' Settled Expectations

    Author Photo

    Recent Patent Trial and Appeal Board decisions show that the U.S. Patent and Trademark Office's new "settled expectations" factor is no longer the exclusive domain of patent owners and can also provide petitioners with viable pathways to argue against discretionary denial, say attorneys at Finnegan.

  • 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims

    Author Photo

    The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.

  • What Ethics Rules Say On Atty Discipline For Online Speech

    Author Photo

    Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.

  • Junior Attys Must Beware Of 5 Common Legal Brief Mistakes

    Excerpt from Practical Guidance
    Author Photo

    Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.